Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

The schizophrenia market size was $9.0 billion in 2021 and is expected to achieve a CAGR of more than 3% during 2021-2031. Schizophrenia is characterized by several symptom domains including positive symptoms (such as hallucinations, delusions, and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including impaired attention, memory, and executive functions).

The schizophrenia market research report provides an overview of the risk factors, comorbidities, and global and historical trends for schizophrenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for total prevalent cases and diagnosed prevalent cases of schizophrenia.

To gain more information on the schizophrenia market forecast, download a free report sample

Schizophrenia Market Drivers

The major drivers of growth in the schizophrenia market include the launch of 11 new pipeline products which will have a higher annual cost of therapy (ACOT). The potential for novel pharmacological therapies specifically indicated for cognitive impairment associated with schizophrenia (CIAS) and the negative symptoms of schizophrenia could provide new options for patients. Moreover, the prospect of novel adjunctive therapies will be welcomed for patients who have a partial response to marketed antipsychotics.

Schizophrenia Market Segmentation by Age

The schizophrenia market can be segmented based on age into 13-17 years, 18-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and above 80 years.

In 2021, for the 7MM combined, adults ages 50–59 years contributed the highest proportion of the 12-month diagnosed prevalent cases of schizophrenia followed by the age group 40–49 years and ages 30-39 years.

Schizophrenia Market Analysis by Age

For more age segment insights into the schizophrenia market, download a free report sample

Schizophrenia Market Segmentation by Sex

The schizophrenia market can be segmented based on sex into men and women.

In the 7MM combined, the number of diagnosed prevalent cases of schizophrenia was higher in women than in men in 2021. The difference in sex distribution is most pronounced in the US, where most diagnosed prevalent cases of schizophrenia occur in women.

Schizophrenia Market Analysis by Sex

For more sex segment insights into the schizophrenia market, download a free report sample

Competitive Landscape

Some of the leading players in the schizophrenia market are Acadia Pharmaceuticals, BioXcel Therapeutics, Boehringer Ingelheim, Eli Lilly, Gedeon Richter, Intra-Cellular Therapies, Johnson & Johnson, Karuna Therapeutics, Lundbeck, Luye Pharma, MedinCell, Minerva Neurosciences, Neurocrine Biosciences, Novartis, Otsuka, Reviva Pharmaceuticals, Sunovion Pharmaceuticals, and Teva.

Schizophrenia Market Report Overview

Scope 

• Overview of schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.